Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection

Table 4 Cox regression analysis of factors associated with time-to-occurrence of hepatitis C virus after inverse probability of treatment weighting in patients who achieved sustained virologic response

Variables	Crude HR (95%CI)	P value	Adjusted HR (95%CI)	P value
Group		0.113		0.144
HCV mono-infection	1 (reference)		1 (reference)
HIV/HCV co-infection	0.19 (0.02-1.48)		0.22 (0.03-1.69)
Age (year)		0.692
< 65	1 (reference)
≥ 65	1.21 (0.47-3.13)
Sex		0.200
Male	1 (reference)
Female	0.58 (0.25-1.34)
Diabetes mellitus		0.034		0.107
Absent	1 (reference)		1 (reference)
Present	2.44 (1.07-5.58)		1.81 (0.88-3.73)
Hypertension		0.217
Absent	1 (reference)
Present	1.72 (0.73-4.08)
Child-Pugh score		0.922
A	1 (reference)
B	1.01 (0.89-1.14)
Treatment		0.507
Peginterferon plus ribavirin	1 (reference)		1 (reference)
DAA	1.31 (0.59-2.94)		1.95 (0.74-5.15)
Fibrosis-4 index		0.016		0.736
≤ 3.25	1 (reference)		1 (reference)
> 3.25	1.41 (1.07-1.86)		1.08 (0.68-1.73)
Liver cirrhosis		0.002		0.004
Absent	1 (reference)		1 (reference)
Present	3.80 (1.63-8.85)		2.54 (1.35-4.77)
AFP (ng/mL)		0.758
< 20	1 (reference)
≥ 20	0.98 (0.87-1.11)
ALBI score		0.149
≤ -2.60	1 (reference)
> -2.60	1.83 (0.81-4.14)
APRI		0.015		0.068
< 1	1 (reference)		1 (reference)
≥ 1	3.33 (1.26-8.77)		2.13 (0.95-4.80)

HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; DAA: Direct-acting antiviral; AFP: Alpha-fetoprotein; ALBI: Albumin-bilirubin score; APRI: Aspartate aminotransferase to platelet ratio index; HR: Hazard ratio; 95%CI: 95% confidence interval.